

R&D Pipeline

Filed • Approved

antibody protein small molecule

As of Dec. 31, 2019

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	Filed in CN	Kirin-Amgen	
		KHK7580 Evocalcet Oral	Calcimimetic	Hypocalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Approved in JP	Licensed from Mitsubishi Tanabe Pharma	
Immunology /Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in KR	Kirin-Amgen	
					Filed in MY		
					Filed in CN		
					Filed in MO		
				Axial Spondyloarthritis (axSpA)	Filed in JP		
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	Filed in EU	In-House	
Other		KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in TW	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
					Filed in CH		
					Filed in KW		
					Filed in SA		
					Filed in CN		
					Filed in HK		
					Filed in SG		
					Adult X-linked Hypophosphatemia (XLH)	Filed in EU	
				Tumor Induced Osteomalacia(TIO)	Filed in US		
				FGF23-Related Hypophosphatemic Rickets and Osteomalacia	Filed in KR		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Filed in TW	Kirin-Amgen	
				Idiopathic (Immune) Thrombocytopenic Purpura	Filed in CN		

Ph II ~ III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	Phase III in JP	Licensed from Reata	
		KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	Phase III in CN, KR, TW and HK	Licensed from Mitsubishi Tanabe Pharma	
		KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia Under Maintenance Dialysis	Phase II in JP	Licensed from Ardelyx	
		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	Phase III in JP	In-House	
Oncology		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase II in JP	Licensed from Syndax	
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others	In-House	POTELLIGENT®
		KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony Stimulating Factor	Mobilization of Hematopoietic stem cell into Peripheral blood	Phase II in JP	Kirin-Amgen	
Immunology/ Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology
				Atopic Dermatitis	Phase II in JP, US, CA and EU		
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Systemic Sclerosis	Phase III in JP	Kirin-Amgen	
				Palmoplantar Pustulosis	Phase III in JP		
		©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
Central Nervous System		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®
		©KW-6356 Oral	Adenosine A_{2A} Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House	
Other		KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	Tumor Induced Osteomalacia(TIO)/Epidermal Nevus Syndrome (ENS)	Phase II in US Phase II in JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Phase II / III in KR	Kirin-Amgen	
				Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	Phase II / III in JP, KR and TW		

antibody
 protein
 small molecule

Ph I

As of Dec. 31, 2019

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2455 Oral	IDO1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
				Urothelial carcinoma	Phase I in US	In-House	Combination with avelumab
		©ME-401 Oral	PI3Kδ Inhibitor	B-cell malignancies	Phase I in JP	Licensed from MEI Pharma	
Immunology/ Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase I in JP	In-House	POTELLIGENT® Human Antibody-Producing Technology
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in JP, EU	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	

Updated since Sep. 30, 2019 (Area, Stage, Filed, Approved, etc.)

New Molecular Entity

Updated since Sep. 30, 2019 (Area, Stage, Filed, Approved, etc.)

Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KHK7580 Evocalcet Oral	Calcimimetic	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Approved in JP	Licensed from Mitsubishi Tanabe Pharma	
Immunology/ Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA)	Filed in JP	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Filed in EU	In-House	
Others		KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	Adult X-linked Hypophosphatemia (XLH)	Filed in EU	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
				Tumor Induced Osteomalacia(TIO)	Filed in US		
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Filed in TW	Kirin-Amgen	
			Idiopathic (Immune) Thrombocytopenic Purpura	Filed in CN			

Ph II~III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	Phase III in JP	In-House	

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology/ Allergy		©KHK4323 Injection		Atopic Dermatitis	Phase I in JP	In-House	